IndieBio

Prellis Biologics, Inc. is a biotechnology company based in San Francisco, California, that specializes in bioprinting human tissues for drug development and organ transplantation. Founded in 2016, the company focuses on overcoming the challenges of creating vascularized human tissues and organs, aiming to revolutionize healthcare. Its innovative technology allows for the precise engineering of human tissues, including lymph node organoids, which can replicate human immune responses for various applications such as antibody discovery and tumor-immune modeling. Prellis Biologics offers a range of products, including TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X, which collectively enhance early-stage drug discovery and translational pharmacology.

Particella is a biotechnology company that specializes in developing a proprietary oral lipid nanoparticle technology designed to deliver mRNA and other nucleic acids. This innovative approach aims to transform the administration of biological medicines by utilizing the intestinal tract to facilitate the secretion of proteins into the bloodstream. By enabling the oral delivery of protein biologics, Particella's technology seeks to address the limitations of current methods, ultimately allowing healthcare providers to prevent gastrointestinal diseases in patients more effectively. The company's advancements hold the potential to create a new category of medicines, enhancing the accessibility and efficacy of treatments.

AlkaLi Labs is a biotechnology research company founded in 2023 and based in San Francisco, California. The company focuses on developing biological solutions to unlock domestic mineral resources. Currently operating in stealth mode, AlkaLi Labs aims to innovate in the field of biotechnology by leveraging natural processes to enhance resource extraction and sustainability.

BioLattice is a biotechnology company focused on developing tissue-engineered cornea technology. Their primary goal is to provide a viable alternative to donor tissue for full-thickness corneal transplants. The company's innovative technology offers a corneal prototype with vision-correcting capabilities, aiming to restore sight for patients requiring corneal transplants.

Laguna Bio is a biotechnology company focused on cancer treatment through its innovative drug discovery platform. Founded in 2022 and headquartered in Berkeley, California, the company specializes in selectively activating and expanding the innate immune system to combat solid tumors. By enhancing the response rate of bispecific antibody drugs, Laguna Bio aims to provide specific T cells that strengthen the immune system's ability to fight cancer, ultimately improving survival rates for patients facing this deadly disease.

FREZENT is a biotechnology company focused on developing innovative therapeutics for advanced-stage cancer patients. It specializes in creating biological inhibitors that target cancer-specific lipid metabolism, aiming to prevent the reactivation of dormant cancer cells.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

DNAzyme is a biotechnology company specializing in the development of enzymes derived from Antarctic extremophile microorganisms as active ingredients for skin health applications. Utilizing recombinant DNA repair technology, the company produces highly pure enzymes at an industrial scale, enabling clinicians to create innovative solutions for skin health and rejuvenation in both the cosmetic and pharmaceutical industries.

heXem bio specializes in recording solutions for the early development of humans for longevity.

CellCrine focuses on discovering enzymes that transform cell culture for the cell-based meats industry. CellCrine was founded in 2021and was headquartered in United, States.

HelEx is a biotechnology company founded in 2021 and based in New York, specializing in genomic medicines tailored for renal indications. The company utilizes its proprietary genomics data and bioinformatics to develop, validate, and distribute therapy-specific guide RNAs (gRNAs). HelEx's innovative platform leverages data-driven deep-learning modeling, utilizing high-throughput next-generation sequencing data derived from CRISPR edits on human cell lines. This approach provides reliable predictions and allows for in-house validation, thereby facilitating the acceleration of drug discovery and the development of cell and gene therapies in the CRISPR-based market.

Calder Biosciences is a biotechnology company focused on developing advanced vaccines to combat life-threatening viruses. Recognizing that traditional vaccines often fail to provide adequate protection against evolving viral threats, Calder employs its proprietary 3D-Vaxlock technology, which utilizes structure-based design to enhance the stability and efficacy of vaccine candidates. This innovative platform creates molecular staples that maintain vaccines in their most effective configurations, addressing the common shortcomings of subunit vaccines, such as limited potency and shelf-life. Calder's current projects include a universal flu vaccine aimed at covering all seasonal strains and a respiratory syncytial virus (RSV) vaccine tailored for the elderly. By prioritizing the development of vaccines with exceptional safety, efficacy, and durability, Calder aims to reduce severe disease and mortality rates while alleviating the burden on healthcare systems, ultimately contributing to healthier lives for vulnerable populations.

Cayuga Biotech is a startup focused on the development of innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a major cause of death from traumatic injuries. The company utilizes a polyphosphate-based drug that enhances the body's natural clotting process at the injury site, thereby minimizing the risk of side effects associated with bleeding. Cayuga's pipeline includes a clinic-ready drug designed for life-threatening hemorrhage and additional therapeutics in the discovery stage targeting rare inherited bleeding disorders, central nervous system bleeding, severe burns, and non-healing wounds. Through its biomimetic therapeutics technology, Cayuga Biotech seeks to harness the body's innate ability to promote healing and improve survival rates, while also reducing disability resulting from trauma.

Reactosome is a biotechnology company that develops synthetic nuclei for gene therapy. Its core product, a synthetic nucleus, operates continuously within cells, mimicking the natural nucleus to affect multiple genes simultaneously. This approach aims to enhance the safety and longevity of gene expression, thereby enabling the development of treatments for complex diseases such as cancer and age-related disorders.

Prellis Biologics, Inc. is a biotechnology company based in San Francisco, California, that specializes in bioprinting human tissues for drug development and organ transplantation. Founded in 2016, the company focuses on overcoming the challenges of creating vascularized human tissues and organs, aiming to revolutionize healthcare. Its innovative technology allows for the precise engineering of human tissues, including lymph node organoids, which can replicate human immune responses for various applications such as antibody discovery and tumor-immune modeling. Prellis Biologics offers a range of products, including TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X, which collectively enhance early-stage drug discovery and translational pharmacology.

Lillianah Technologies is a company dedicated to developing innovative carbon capture technology aimed at restoring marine ecosystems affected by pollution and other environmental challenges. Comprising a team of scientists, Lillianah focuses on optimizing the biological pump in oceans, which is crucial for maintaining ecological balance. By harnessing the ocean's potential, the company seeks to address the detrimental impacts of human activity, such as fertilizer runoff, and contribute to reversing environmental degradation. Through its efforts, Lillianah Technologies aspires to create sustainable solutions that benefit both the oceans and the broader environment.

RizLab Health is a medical device startup founded in 2018 and based in East Princeton. The company specializes in providing rapid blood count analysis through its innovative electronic cytometer and analyzer. This device utilizes a cartridge system to quantify key cellular components of white blood cells, facilitating quick and accurate assessments of patients' health. RizLab Health's technology is designed to be portable and cost-effective, enabling healthcare practitioners to monitor white blood counts, neutrophils, and lymphocytes efficiently. This capability is particularly valuable in clinical scenarios such as diagnosing sepsis or determining the presence of bacterial or viral infections, enhancing decision-making in patient care.

FREZENT is a biotechnology company focused on developing innovative therapeutics for advanced-stage cancer patients. It specializes in creating biological inhibitors that target cancer-specific lipid metabolism, aiming to prevent the reactivation of dormant cancer cells.

BioAesthetics LLC, founded in 2015 as a spin-out from Tulane University, is dedicated to improving reconstruction options for breast cancer patients post-mastectomy. The company specializes in developing tissue-engineered nipple-areolar complex (NAC) grafts, which are designed to be used during the breast reconstruction phase. These off-the-shelf, acellular NAC grafts serve as a framework for the patient's own cells to regenerate their nipple and areola, providing a more natural outcome. The company is based in New Orleans, Louisiana.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

Calder Biosciences is a biotechnology company focused on developing advanced vaccines to combat life-threatening viruses. Recognizing that traditional vaccines often fail to provide adequate protection against evolving viral threats, Calder employs its proprietary 3D-Vaxlock technology, which utilizes structure-based design to enhance the stability and efficacy of vaccine candidates. This innovative platform creates molecular staples that maintain vaccines in their most effective configurations, addressing the common shortcomings of subunit vaccines, such as limited potency and shelf-life. Calder's current projects include a universal flu vaccine aimed at covering all seasonal strains and a respiratory syncytial virus (RSV) vaccine tailored for the elderly. By prioritizing the development of vaccines with exceptional safety, efficacy, and durability, Calder aims to reduce severe disease and mortality rates while alleviating the burden on healthcare systems, ultimately contributing to healthier lives for vulnerable populations.

BryoSphere is a company specializing in the manufacturing of specialty chemicals, employing moss plants and biotechnology methods in the production of their goods. The company is currently focused on the development of two key products: one for addressing skin hyperpigmentation in topical treatments, and another as an anti-cancer drug.

Xias Bio is a biotechnology startup focused on the development and production of recombinant proteins. The company specializes in creating non-immunogenic natural motifs that enhance the delivery of functionalities for various applications in research, beauty, and healthcare. Xias Bio's innovative platform provides a versatile, animal product-free biomaterial that offers tailored biological functionality. This approach enables pharmaceutical and cosmetic companies to access designer proteins that serve as non-immunogenic, non-toxic alternatives to traditional synthetic and animal-derived materials. By improving attributes such as gel and film formation, as well as antioxidant properties, Xias Bio addresses the limitations of conventional solutions, positioning itself as a valuable partner in the biotechnology sector.

Cell BioEngines, Inc. is a clinical-stage biotechnology company dedicated to the development of allogeneic "off-the-shelf" stem cell therapies aimed at treating various human diseases. The company employs a unique blood stem cell-derived epigenetic platform designed to enhance donor source availability, improve cellular potency, and simplify the manufacturing processes of clinical-grade cell products. In addition, Cell BioEngines is advancing a pre-clinical stage immunotherapy platform focused on making all cancers treatable, thereby offering the potential for long-lasting benefits in oncology. Through its innovative approach, Cell BioEngines seeks to address significant challenges in the field of cell-based therapies and improve patient outcomes.

TippingPoint Biosciences is focused on developing innovative therapeutics that address diseases caused by defects in DNA packaging, with an emphasis on conditions such as cancer and neurodegenerative disorders. Utilizing a specialized drug discovery platform, the company aims to identify new treatment options that specifically target unique genome packaging states associated with various diseases. This approach not only facilitates the treatment of cancer but also holds potential for advancing stem cell therapies by correcting dysfunctional genome packaging. Through its research and development efforts, TippingPoint Biosciences seeks to provide effective solutions for complex medical challenges.

AlkaLi Labs is a biotechnology research company founded in 2023 and based in San Francisco, California. The company focuses on developing biological solutions to unlock domestic mineral resources. Currently operating in stealth mode, AlkaLi Labs aims to innovate in the field of biotechnology by leveraging natural processes to enhance resource extraction and sustainability.

Gozen Bioworks offers solutions and biomaterials developed with a biomimicry approach by combining science, art, philosophy, and design to raise awareness and provide help to the planet, living creatures, and humanity. They develop and invent high-performance microbe-derived materials from natural inputs, such as next-generation leather, biotextiles, bioplastics, packaging, and interior materials.

Kresko RNAtech is a biotechnology company focused on the development and production of nutraceuticals. It specializes in identifying bioactive ribonucleic acids (RNAs) from natural sources, utilizing advanced techniques such as machine learning and bioinformatics. By discovering RNAs that may offer health benefits, Kresko RNAtech aims to assist researchers in enhancing human well-being and addressing the challenges posed by stressful and changing environments through innovative RNA technologies.

Stämm Biotech is a San Francisco-based company specializing in advanced bioproduction systems designed to address the scaling challenges in the biotech industry. Founded in 2014, Stämm has developed an innovative biomanufacturing solution that integrates microfluidics, electroporation, and robotics, resulting in a compact, all-in-one Bioprocessor. This system has demonstrated productivity levels at least 70 times greater than traditional bioreactors, enabling clients to miniaturize bioreactors and optimize conditions more efficiently. Stämm's technology incorporates various sensors to monitor biological, physical, and chemical variations throughout the bioprocess, facilitating a streamlined approach to microbial growth and monoclonal cell line development. By transforming large-scale biotech operations into a more manageable micro-factory network, Stämm aims to unlock significant market potential in the coming years.

Cayuga Biotech is a startup focused on the development of innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a major cause of death from traumatic injuries. The company utilizes a polyphosphate-based drug that enhances the body's natural clotting process at the injury site, thereby minimizing the risk of side effects associated with bleeding. Cayuga's pipeline includes a clinic-ready drug designed for life-threatening hemorrhage and additional therapeutics in the discovery stage targeting rare inherited bleeding disorders, central nervous system bleeding, severe burns, and non-healing wounds. Through its biomimetic therapeutics technology, Cayuga Biotech seeks to harness the body's innate ability to promote healing and improve survival rates, while also reducing disability resulting from trauma.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative gene therapy treatments for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes advanced oral lipid nanoparticle technology to deliver mRNA and plasmid DNA directly to intestinal stem cells. This approach aims to address the root causes of gastrointestinal diseases, including Familial Adenomatous Polyposis (FAP), a hereditary condition that can lead to colorectal cancer and often necessitates invasive surgical interventions. DNALite's therapies seek to transform protein biologics into oral drugs, allowing for more effective and less invasive treatment options.

Particella is a biotechnology company that specializes in developing a proprietary oral lipid nanoparticle technology designed to deliver mRNA and other nucleic acids. This innovative approach aims to transform the administration of biological medicines by utilizing the intestinal tract to facilitate the secretion of proteins into the bloodstream. By enabling the oral delivery of protein biologics, Particella's technology seeks to address the limitations of current methods, ultimately allowing healthcare providers to prevent gastrointestinal diseases in patients more effectively. The company's advancements hold the potential to create a new category of medicines, enhancing the accessibility and efficacy of treatments.

FluoSphera is a biotechnology company focused on developing safer and more effective drugs. It aims to minimize adverse side effects and reduce reliance on animal testing by leveraging innovative drug discovery technologies. This enables FluoSphera's partners to better understand human physiological responses and safeguard populations from harmful chemicals more efficiently.

Lillianah Technologies is a company dedicated to developing innovative carbon capture technology aimed at restoring marine ecosystems affected by pollution and other environmental challenges. Comprising a team of scientists, Lillianah focuses on optimizing the biological pump in oceans, which is crucial for maintaining ecological balance. By harnessing the ocean's potential, the company seeks to address the detrimental impacts of human activity, such as fertilizer runoff, and contribute to reversing environmental degradation. Through its efforts, Lillianah Technologies aspires to create sustainable solutions that benefit both the oceans and the broader environment.

Michroma Corporation is a biotechnology company that specializes in producing natural thermostable colorants derived from filamentous fungi for the food and cosmetics industries. Founded in 2019, the company operates from locations in San Francisco, California, and Rosario, Argentina. By leveraging synthetic biology, Michroma develops proprietary fungal strains that can be cultivated in bioreactors, allowing for the sustainable and cost-effective production of high-performance ingredients. Its initial offerings focus on pH-stable and heat-stable colorants, which are designed to replace synthetic pigments and those sourced from animals and plants. In addition to colorants, Michroma is also engaged in the production of mycoprotein and other innovative ingredients, collaborating with leading companies in the food and beverage and cosmetic sectors.

FluoSphera is a biotechnology company focused on developing safer and more effective drugs. It aims to minimize adverse side effects and reduce reliance on animal testing by leveraging innovative drug discovery technologies. This enables FluoSphera's partners to better understand human physiological responses and safeguard populations from harmful chemicals more efficiently.

OneSkin Inc. is a biotechnology company based in San Francisco, California, that focuses on developing innovative solutions to combat skin aging. Founded by a team of four PhDs and longevity scientists, the company specializes in creating advanced human 3D skin models for research, development, and validation of skincare products, including new anti-aging compounds. OneSkin has developed a proprietary peptide, OS-01, which is designed to reduce the biological age of the skin by decreasing the accumulation of aged cells, enhancing cellular repair capacity, and strengthening the epidermal barrier. The company's flagship product, OS-01 Topical Supplement, is formulated to target the root causes of skin aging and is suitable for all skin types. In addition to its product offerings, OneSkin provides in vitro testing services using its animal-free 3D human tissue models, facilitating efficacy and safety assessments for the cosmetic and ingredient supplier industries.

HelEx is a biotechnology company founded in 2021 and based in New York, specializing in genomic medicines tailored for renal indications. The company utilizes its proprietary genomics data and bioinformatics to develop, validate, and distribute therapy-specific guide RNAs (gRNAs). HelEx's innovative platform leverages data-driven deep-learning modeling, utilizing high-throughput next-generation sequencing data derived from CRISPR edits on human cell lines. This approach provides reliable predictions and allows for in-house validation, thereby facilitating the acceleration of drug discovery and the development of cell and gene therapies in the CRISPR-based market.

Wayfinder Biosciences is a biotechnology company focused on developing orally available small molecule drugs that target RNA to address key disease areas, including oncology and neurodegenerative disorders. Established in 2021 and headquartered in Seattle, WA, the company utilizes a proprietary platform that integrates advanced screening technologies and computational methods to discover potent and selective RNA-targeting molecules. By employing high-throughput screening combined with machine learning and unique datasets, Wayfinder aims to accelerate the development of therapeutics for traditionally inaccessible targets, enhancing the potential for treating genetic diseases and other challenging conditions.

Michroma Corporation is a biotechnology company that specializes in producing natural thermostable colorants derived from filamentous fungi for the food and cosmetics industries. Founded in 2019, the company operates from locations in San Francisco, California, and Rosario, Argentina. By leveraging synthetic biology, Michroma develops proprietary fungal strains that can be cultivated in bioreactors, allowing for the sustainable and cost-effective production of high-performance ingredients. Its initial offerings focus on pH-stable and heat-stable colorants, which are designed to replace synthetic pigments and those sourced from animals and plants. In addition to colorants, Michroma is also engaged in the production of mycoprotein and other innovative ingredients, collaborating with leading companies in the food and beverage and cosmetic sectors.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

Gozen Bioworks offers solutions and biomaterials developed with a biomimicry approach by combining science, art, philosophy, and design to raise awareness and provide help to the planet, living creatures, and humanity. They develop and invent high-performance microbe-derived materials from natural inputs, such as next-generation leather, biotextiles, bioplastics, packaging, and interior materials.

Laguna Bio is a biotechnology company focused on cancer treatment through its innovative drug discovery platform. Founded in 2022 and headquartered in Berkeley, California, the company specializes in selectively activating and expanding the innate immune system to combat solid tumors. By enhancing the response rate of bispecific antibody drugs, Laguna Bio aims to provide specific T cells that strengthen the immune system's ability to fight cancer, ultimately improving survival rates for patients facing this deadly disease.

CellCrine focuses on discovering enzymes that transform cell culture for the cell-based meats industry. CellCrine was founded in 2021and was headquartered in United, States.

Prellis Biologics, Inc. is a biotechnology company based in San Francisco, California, that specializes in bioprinting human tissues for drug development and organ transplantation. Founded in 2016, the company focuses on overcoming the challenges of creating vascularized human tissues and organs, aiming to revolutionize healthcare. Its innovative technology allows for the precise engineering of human tissues, including lymph node organoids, which can replicate human immune responses for various applications such as antibody discovery and tumor-immune modeling. Prellis Biologics offers a range of products, including TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X, which collectively enhance early-stage drug discovery and translational pharmacology.

SyntheX, Inc. is a biotechnology company based in San Francisco, California, founded in 2016. It operates a proprietary drug discovery platform that utilizes synthetic biology to expand the druggable proteome, focusing on therapeutic applications in oncology and rare diseases. The platform employs empirical intracellular selection to identify and design compounds that can modulate protein interactions, either disrupting specific protein-protein interactions or facilitating the targeted degradation of proteins through the recruitment of E3 ubiquitin ligases. SyntheX's development portfolio includes stabilized peptide therapeutics, such as STX101 and STX105, aimed at treating cancers that evade chemotherapy through homologous recombination. The company identifies drug targets by analyzing clinical, evolutionary, phenotypic, and structural data, and it maintains both internal oncology projects and collaborative discovery initiatives.

BioLumen is a nutritional technology company that develops a patented dietary fiber technology platform that reduces the negative effect of a diet heavy in processed foods. BioLumen's technology is composed of insoluble dietary fiber matrix covered with a blend of food ingredients created from the latest drug delivery system research. The company's product, a nutraceutical, focuses on high risk individuals with prediabetes to help manage blood sugar levels, protect their liver from excess sugar and feed their gut microbiome, delivering health benefits. BioLumen was founded on 2018 and is headquartered in San Francisco, California.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

AnimalBiome specializes in personalized nutrition services that focus on enhancing the gut health of dogs and cats through microbiome science. The company offers microbiome tests that assess the unique gut microbiota of individual pets, providing insights that inform tailored nutrition recommendations. Additionally, AnimalBiome develops restorative supplements made from material sourced from healthy animals, allowing for the introduction of beneficial microbes to help restore balance in the gut microbiome. By leveraging advanced diagnostic tools, including DNA sequencing, AnimalBiome enables pet owners to better understand their pets' gut health, ultimately contributing to improved well-being and a healthier lifestyle for their animals.

Kalia Health is a biotechnology company based in Chapel Hill, North Carolina, founded in 2019. The company focuses on improving maternal health outcomes by developing safe, affordable, and accessible home-based early detection tests for complications during pregnancy. One of its key products is a low-cost, reliable preeclampsia detection strip, which enables expectant mothers to self-screen for this serious condition. By facilitating early detection, Kalia Health aims to empower women to seek timely medical intervention, ultimately reducing the risks associated with preeclampsia and enhancing maternal health.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative gene therapy treatments for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes advanced oral lipid nanoparticle technology to deliver mRNA and plasmid DNA directly to intestinal stem cells. This approach aims to address the root causes of gastrointestinal diseases, including Familial Adenomatous Polyposis (FAP), a hereditary condition that can lead to colorectal cancer and often necessitates invasive surgical interventions. DNALite's therapies seek to transform protein biologics into oral drugs, allowing for more effective and less invasive treatment options.

Kalia Health is a biotechnology company based in Chapel Hill, North Carolina, founded in 2019. The company focuses on improving maternal health outcomes by developing safe, affordable, and accessible home-based early detection tests for complications during pregnancy. One of its key products is a low-cost, reliable preeclampsia detection strip, which enables expectant mothers to self-screen for this serious condition. By facilitating early detection, Kalia Health aims to empower women to seek timely medical intervention, ultimately reducing the risks associated with preeclampsia and enhancing maternal health.

Innatrix is an agricultural biotechnology company focused on developing innovative biological and chemical solutions to address crop diseases, pests, and weeds that are otherwise difficult to manage. Utilizing patented protein evolution technology, the company has established a peptide and RNA interference delivery platform that offers eco-friendly alternatives for crop protection. Innatrix's proprietary automated platform facilitates protein engineering through continuous laboratory evolution and advanced techniques such as phage display. This technology empowers researchers with enhanced control, reporting, recording, simulation, and remote access capabilities, thereby advancing the field of agricultural biotechnology and promoting sustainable farming practices.

Innatrix is an agricultural biotechnology company focused on developing innovative biological and chemical solutions to address crop diseases, pests, and weeds that are otherwise difficult to manage. Utilizing patented protein evolution technology, the company has established a peptide and RNA interference delivery platform that offers eco-friendly alternatives for crop protection. Innatrix's proprietary automated platform facilitates protein engineering through continuous laboratory evolution and advanced techniques such as phage display. This technology empowers researchers with enhanced control, reporting, recording, simulation, and remote access capabilities, thereby advancing the field of agricultural biotechnology and promoting sustainable farming practices.

Cayuga Biotech is a startup focused on the development of innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a major cause of death from traumatic injuries. The company utilizes a polyphosphate-based drug that enhances the body's natural clotting process at the injury site, thereby minimizing the risk of side effects associated with bleeding. Cayuga's pipeline includes a clinic-ready drug designed for life-threatening hemorrhage and additional therapeutics in the discovery stage targeting rare inherited bleeding disorders, central nervous system bleeding, severe burns, and non-healing wounds. Through its biomimetic therapeutics technology, Cayuga Biotech seeks to harness the body's innate ability to promote healing and improve survival rates, while also reducing disability resulting from trauma.

Cellens is a medical device company based in Medford, Massachusetts, and is a spinoff from Tufts University, established in 2019. The company focuses on enhancing cancer detection through noninvasive screening methods. It has developed a cell surface scanning platform that utilizes atomic force microscopy imaging and machine learning to assist oncologists in the detection of bladder cancer. By analyzing physio-biomarkers on cell surfaces derived from urine samples, Cellens provides a diagnostic score that helps healthcare professionals minimize the need for invasive and costly procedures, thereby improving patient outcomes in bladder cancer diagnostics.

Cellens is a medical device company based in Medford, Massachusetts, and is a spinoff from Tufts University, established in 2019. The company focuses on enhancing cancer detection through noninvasive screening methods. It has developed a cell surface scanning platform that utilizes atomic force microscopy imaging and machine learning to assist oncologists in the detection of bladder cancer. By analyzing physio-biomarkers on cell surfaces derived from urine samples, Cellens provides a diagnostic score that helps healthcare professionals minimize the need for invasive and costly procedures, thereby improving patient outcomes in bladder cancer diagnostics.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

Grand Bio is working to improve the efficiency with which cells create their own growth factors. The firm provides supplements that boost growth factors in the medium in which cells live and thrive.

Grand Bio is working to improve the efficiency with which cells create their own growth factors. The firm provides supplements that boost growth factors in the medium in which cells live and thrive.

Prothegen is a biotechnology company located in Palo Alto, California, focused on developing innovative medicines that precisely regulate cell death. The company has created a platform aimed at delivering therapies that can either inhibit or promote ferroptosis, a form of regulated cell death. By targeting this mechanism, Prothegen seeks to provide effective therapeutics that can prevent unwanted cell death, thereby improving treatment options for various diseases.

Prothegen is a biotechnology company located in Palo Alto, California, focused on developing innovative medicines that precisely regulate cell death. The company has created a platform aimed at delivering therapies that can either inhibit or promote ferroptosis, a form of regulated cell death. By targeting this mechanism, Prothegen seeks to provide effective therapeutics that can prevent unwanted cell death, thereby improving treatment options for various diseases.

Indee Labs is focused on developing innovative hardware for gene delivery, specifically designed to facilitate the efficient development and scalable manufacture of gene-modified cell therapies, such as chimeric antigen receptor T cells. The company has created a non-viral intracellular delivery system that integrates with standard reagents, optimizing the recovery of viable modified cells with minimal disruption. Utilizing microfluidic vortex shedding technology, Indee Labs' system enables the gentle delivery of macromolecules, nucleic acids, and gene-editing complexes to various cell types. The company collaborates with the Australian National Fabrication Facility for its technology development and has established lab space at Bonneville Labs in Berkeley while expanding its operations with a new office in Sydney. Indee Labs has been associated with various prestigious incubators and programs, including NSW Health, IndieBio, Y Combinator, and MBC Biolabs.

HelEx is a biotechnology company founded in 2021 and based in New York, specializing in genomic medicines tailored for renal indications. The company utilizes its proprietary genomics data and bioinformatics to develop, validate, and distribute therapy-specific guide RNAs (gRNAs). HelEx's innovative platform leverages data-driven deep-learning modeling, utilizing high-throughput next-generation sequencing data derived from CRISPR edits on human cell lines. This approach provides reliable predictions and allows for in-house validation, thereby facilitating the acceleration of drug discovery and the development of cell and gene therapies in the CRISPR-based market.

HelEx is a biotechnology company founded in 2021 and based in New York, specializing in genomic medicines tailored for renal indications. The company utilizes its proprietary genomics data and bioinformatics to develop, validate, and distribute therapy-specific guide RNAs (gRNAs). HelEx's innovative platform leverages data-driven deep-learning modeling, utilizing high-throughput next-generation sequencing data derived from CRISPR edits on human cell lines. This approach provides reliable predictions and allows for in-house validation, thereby facilitating the acceleration of drug discovery and the development of cell and gene therapies in the CRISPR-based market.

RizLab Health is a medical device startup founded in 2018 and based in East Princeton. The company specializes in providing rapid blood count analysis through its innovative electronic cytometer and analyzer. This device utilizes a cartridge system to quantify key cellular components of white blood cells, facilitating quick and accurate assessments of patients' health. RizLab Health's technology is designed to be portable and cost-effective, enabling healthcare practitioners to monitor white blood counts, neutrophils, and lymphocytes efficiently. This capability is particularly valuable in clinical scenarios such as diagnosing sepsis or determining the presence of bacterial or viral infections, enhancing decision-making in patient care.

RizLab Health is a medical device startup founded in 2018 and based in East Princeton. The company specializes in providing rapid blood count analysis through its innovative electronic cytometer and analyzer. This device utilizes a cartridge system to quantify key cellular components of white blood cells, facilitating quick and accurate assessments of patients' health. RizLab Health's technology is designed to be portable and cost-effective, enabling healthcare practitioners to monitor white blood counts, neutrophils, and lymphocytes efficiently. This capability is particularly valuable in clinical scenarios such as diagnosing sepsis or determining the presence of bacterial or viral infections, enhancing decision-making in patient care.

Stämm Biotech is a San Francisco-based company specializing in advanced bioproduction systems designed to address the scaling challenges in the biotech industry. Founded in 2014, Stämm has developed an innovative biomanufacturing solution that integrates microfluidics, electroporation, and robotics, resulting in a compact, all-in-one Bioprocessor. This system has demonstrated productivity levels at least 70 times greater than traditional bioreactors, enabling clients to miniaturize bioreactors and optimize conditions more efficiently. Stämm's technology incorporates various sensors to monitor biological, physical, and chemical variations throughout the bioprocess, facilitating a streamlined approach to microbial growth and monoclonal cell line development. By transforming large-scale biotech operations into a more manageable micro-factory network, Stämm aims to unlock significant market potential in the coming years.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative gene therapy treatments for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes advanced oral lipid nanoparticle technology to deliver mRNA and plasmid DNA directly to intestinal stem cells. This approach aims to address the root causes of gastrointestinal diseases, including Familial Adenomatous Polyposis (FAP), a hereditary condition that can lead to colorectal cancer and often necessitates invasive surgical interventions. DNALite's therapies seek to transform protein biologics into oral drugs, allowing for more effective and less invasive treatment options.

Wayfinder Biosciences is a biotechnology company focused on developing orally available small molecule drugs that target RNA to address key disease areas, including oncology and neurodegenerative disorders. Established in 2021 and headquartered in Seattle, WA, the company utilizes a proprietary platform that integrates advanced screening technologies and computational methods to discover potent and selective RNA-targeting molecules. By employing high-throughput screening combined with machine learning and unique datasets, Wayfinder aims to accelerate the development of therapeutics for traditionally inaccessible targets, enhancing the potential for treating genetic diseases and other challenging conditions.

Basin Genomics is combining scientific backgrounds in genomics and oncology with startup expertise to translate genetic discoveries into advances in personalized clinical care as it strives to develop technology that will decrease the rates of cervical cancer globally.

Basin Genomics is combining scientific backgrounds in genomics and oncology with startup expertise to translate genetic discoveries into advances in personalized clinical care as it strives to develop technology that will decrease the rates of cervical cancer globally.

Dalton Bioanalytics is a company that specializes in analytical technology aimed at transforming blood analysis and enhancing preventative healthcare. Founded in 2019 and based in Los Angeles, California, Dalton Bioanalytics addresses the inefficiencies and high costs associated with traditional laboratory testing. Its innovative technology digitizes the biochemical composition of blood, allowing for a comprehensive array of health insights derived from a single assay. This capability enables the monitoring of various plasma analytes, including proteins, lipids, electrolytes, and small molecules. By deciphering the biochemical signatures in blood, Dalton Bioanalytics supports the scientific research community in exploring multi-omic biology, thereby facilitating the discovery, development, and delivery of precision medicine.

Sequential Skin is a diagnostic platform focused on skin longevity and aging, leveraging expertise in genetics, epigenetics, and the skin microbiome. The company specializes in clinical microbiome testing for skin, scalp, and female health. Its primary offering is a skin health test that employs quantitative real-time PCR (qPCR) technology to analyze specific markers within the skin microbiome. This analysis provides individuals with a detailed understanding of their skin profile, helping them identify their unique skincare needs. By delivering personalized insights, Sequential Skin empowers individuals to make informed decisions about their skincare routines.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

Gatehouse Bio is a biotech company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of therapies utilizing a novel bioinformatics platform that focuses on small ribonucleic acid (RNA) biomarkers. This platform is designed to classify patient samples with binary accuracy and identifies disease-associated mutations, enabling the creation of targeted therapeutics. By employing artificial intelligence, Gatehouse Bio aims to analyze small RNA genes and design oligonucleotides that can effectively counteract the effects of these mutations. Their research and development efforts target therapeutic areas with known heterogeneity, such as fibrosis, inflammation, and neurodegeneration, with the goal of unlocking the potential for improved patient outcomes through personalized medicine.

Biomage is a company dedicated to advancing life sciences through innovative single-cell analysis. It offers a platform that enables researchers to analyze vast single-cell sequencing data efficiently, transforming complex biological data into actionable insights. This capability supports both academic and industrial scientists in enhancing drug target discovery while reducing costs. The Biomage Single Cell Platform allows users to manage their single-cell data analysis with ease, providing deep biological insights in a streamlined manner. By applying advanced computational methods, Biomage is at the forefront of facilitating groundbreaking research across various biological disciplines.

Microbiome-focused therapeutics for diseases of the oral cavity and their systemic effects

Stembionix is a biotechnology company focused on developing advanced longevity products aimed at enhancing both the lifespan and quality of life for individuals. The company specializes in innovative technologies that biologically integrate with users, facilitating a bi-directional exchange of information. This integration allows patients to access their personal stem cells, thereby advancing the field of personalized longevity solutions. Stembionix is dedicated to rapidly advancing its technologies to help individuals live healthier and longer lives.

Stembionix is a biotechnology company focused on developing advanced longevity products aimed at enhancing both the lifespan and quality of life for individuals. The company specializes in innovative technologies that biologically integrate with users, facilitating a bi-directional exchange of information. This integration allows patients to access their personal stem cells, thereby advancing the field of personalized longevity solutions. Stembionix is dedicated to rapidly advancing its technologies to help individuals live healthier and longer lives.

Mendel is a clinical AI platform for life sciences and healthcare organizations that deciphers health data with clinician-like logic. It indexes structured and unstructured data and replaces the complexity of querying with the simplicity of chatting.

AsimicA, founded by Nikolai Mushnikov and Grant Bowman in November 2018, specializes in developing innovative technologies aimed at enhancing production efficiency in microbial biosynthetic factories. The company's core focus is on improving yields of biosynthetic processes, a significant challenge in biotechnology due to relatively low product outputs. AsimicA's novel approaches, centered around microbial stem cell technology, have the potential to revolutionize the industry by enabling multi-fold increases in production efficiency, particularly for pharmaceutical biomolecules.

Allied Microbiota, LLC is a biotechnology company focused on developing innovative microbial products designed for environmental remediation. Originating from research at Columbia University, the company's flagship product, PacBac, offers a microbial-based solution that efficiently reduces harmful organic chemicals in soil, significantly outperforming traditional remediation methods such as incineration. By enabling the rapid breakdown of recalcitrant contaminants, including poly-chlorinated biphenyls, PacBac can achieve an 80% reduction in these pollutants within days, providing substantial cost savings compared to conventional technologies. With an estimated market potential of $20 billion annually, Allied Microbiota aims to transform the soil remediation landscape through its sustainable approach, which eliminates contaminants without relying on limited landfill options. Additionally, the company is engaged in ongoing research and development to identify new microbial strains and create bio-based products leveraging advanced techniques in synthetic biology, data science, and analytical chemistry.

Biomage is a company dedicated to advancing life sciences through innovative single-cell analysis. It offers a platform that enables researchers to analyze vast single-cell sequencing data efficiently, transforming complex biological data into actionable insights. This capability supports both academic and industrial scientists in enhancing drug target discovery while reducing costs. The Biomage Single Cell Platform allows users to manage their single-cell data analysis with ease, providing deep biological insights in a streamlined manner. By applying advanced computational methods, Biomage is at the forefront of facilitating groundbreaking research across various biological disciplines.

BioAesthetics LLC, founded in 2015 as a spin-out from Tulane University, is dedicated to improving reconstruction options for breast cancer patients post-mastectomy. The company specializes in developing tissue-engineered nipple-areolar complex (NAC) grafts, which are designed to be used during the breast reconstruction phase. These off-the-shelf, acellular NAC grafts serve as a framework for the patient's own cells to regenerate their nipple and areola, providing a more natural outcome. The company is based in New Orleans, Louisiana.

Biomage is a company dedicated to advancing life sciences through innovative single-cell analysis. It offers a platform that enables researchers to analyze vast single-cell sequencing data efficiently, transforming complex biological data into actionable insights. This capability supports both academic and industrial scientists in enhancing drug target discovery while reducing costs. The Biomage Single Cell Platform allows users to manage their single-cell data analysis with ease, providing deep biological insights in a streamlined manner. By applying advanced computational methods, Biomage is at the forefront of facilitating groundbreaking research across various biological disciplines.

Synthetix is a decentralized synthetic asset issuance protocol based in Australia, established in 2017 by Kain Warwick. Built on the Ethereum blockchain, it facilitates derivatives trading in decentralized finance (DeFi) by enabling the creation of synthetic assets that provide exposure to real-world currencies, commodities, stocks, and indices. The platform offers unique financial instruments such as perpetual futures and options markets, allowing users to trade synthetic forms of assets with infinite liquidity. Synthetix operates a peer-to-contract trading system and utilizes a distributed collateral pool, ensuring transparency and accessibility for customers seeking on-chain exposure to various decentralized assets.

OneSkin Inc. is a biotechnology company based in San Francisco, California, that focuses on developing innovative solutions to combat skin aging. Founded by a team of four PhDs and longevity scientists, the company specializes in creating advanced human 3D skin models for research, development, and validation of skincare products, including new anti-aging compounds. OneSkin has developed a proprietary peptide, OS-01, which is designed to reduce the biological age of the skin by decreasing the accumulation of aged cells, enhancing cellular repair capacity, and strengthening the epidermal barrier. The company's flagship product, OS-01 Topical Supplement, is formulated to target the root causes of skin aging and is suitable for all skin types. In addition to its product offerings, OneSkin provides in vitro testing services using its animal-free 3D human tissue models, facilitating efficacy and safety assessments for the cosmetic and ingredient supplier industries.

BrightCure Ltd., established in 2019 and based in London, United Kingdom, specializes in developing probiotic-based therapies aimed at treating urinary tract infections (UTIs). The company focuses on addressing recurrent and difficult-to-treat bacterial infections, a significant health issue affecting 50% of women and 12% of men globally. BrightCure's approach involves utilizing the natural microbiome to reduce harmful bacteria and replenish beneficial bacteria in the vaginal flora, thereby boosting the immune system to promote urinary tract health. The company has garnered recognition through various competitions and accelerators, including selection for Indiebio, the world's largest biotech accelerator.

BrightCure Ltd., established in 2019 and based in London, United Kingdom, specializes in developing probiotic-based therapies aimed at treating urinary tract infections (UTIs). The company focuses on addressing recurrent and difficult-to-treat bacterial infections, a significant health issue affecting 50% of women and 12% of men globally. BrightCure's approach involves utilizing the natural microbiome to reduce harmful bacteria and replenish beneficial bacteria in the vaginal flora, thereby boosting the immune system to promote urinary tract health. The company has garnered recognition through various competitions and accelerators, including selection for Indiebio, the world's largest biotech accelerator.

Cayuga Biotech is a startup focused on the development of innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a major cause of death from traumatic injuries. The company utilizes a polyphosphate-based drug that enhances the body's natural clotting process at the injury site, thereby minimizing the risk of side effects associated with bleeding. Cayuga's pipeline includes a clinic-ready drug designed for life-threatening hemorrhage and additional therapeutics in the discovery stage targeting rare inherited bleeding disorders, central nervous system bleeding, severe burns, and non-healing wounds. Through its biomimetic therapeutics technology, Cayuga Biotech seeks to harness the body's innate ability to promote healing and improve survival rates, while also reducing disability resulting from trauma.

Cayuga Biotech is a startup focused on the development of innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a major cause of death from traumatic injuries. The company utilizes a polyphosphate-based drug that enhances the body's natural clotting process at the injury site, thereby minimizing the risk of side effects associated with bleeding. Cayuga's pipeline includes a clinic-ready drug designed for life-threatening hemorrhage and additional therapeutics in the discovery stage targeting rare inherited bleeding disorders, central nervous system bleeding, severe burns, and non-healing wounds. Through its biomimetic therapeutics technology, Cayuga Biotech seeks to harness the body's innate ability to promote healing and improve survival rates, while also reducing disability resulting from trauma.

Biomage is a company dedicated to advancing life sciences through innovative single-cell analysis. It offers a platform that enables researchers to analyze vast single-cell sequencing data efficiently, transforming complex biological data into actionable insights. This capability supports both academic and industrial scientists in enhancing drug target discovery while reducing costs. The Biomage Single Cell Platform allows users to manage their single-cell data analysis with ease, providing deep biological insights in a streamlined manner. By applying advanced computational methods, Biomage is at the forefront of facilitating groundbreaking research across various biological disciplines.

Dalton Bioanalytics is a company that specializes in analytical technology aimed at transforming blood analysis and enhancing preventative healthcare. Founded in 2019 and based in Los Angeles, California, Dalton Bioanalytics addresses the inefficiencies and high costs associated with traditional laboratory testing. Its innovative technology digitizes the biochemical composition of blood, allowing for a comprehensive array of health insights derived from a single assay. This capability enables the monitoring of various plasma analytes, including proteins, lipids, electrolytes, and small molecules. By deciphering the biochemical signatures in blood, Dalton Bioanalytics supports the scientific research community in exploring multi-omic biology, thereby facilitating the discovery, development, and delivery of precision medicine.

Membio's single-use 0.2-10 L benchtop bioreactor system uses a proprietary design to provide a constant environment for cells at all scales. One technique will provide the same outcomes at all scales, whether at 0.2 L, 10 L, or anywhere in between. Fully automated single-use bioreactors designed by the business to enable cost-effective and scalable manufacture.

Prellis Biologics, Inc. is a biotechnology company based in San Francisco, California, that specializes in bioprinting human tissues for drug development and organ transplantation. Founded in 2016, the company focuses on overcoming the challenges of creating vascularized human tissues and organs, aiming to revolutionize healthcare. Its innovative technology allows for the precise engineering of human tissues, including lymph node organoids, which can replicate human immune responses for various applications such as antibody discovery and tumor-immune modeling. Prellis Biologics offers a range of products, including TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X, which collectively enhance early-stage drug discovery and translational pharmacology.

Ivy Natal is a biotechnology company focused on addressing infertility through innovative reproductive solutions. The company has developed a skin biopsy technology that enables the creation of human egg cells from skin samples. This process activates the existing DNA within skin cells to transform them into healthy egg cells, offering a novel alternative to traditional in vitro methods for producing eggs and sperm. By circumventing the challenges associated with conventional reproductive techniques, Ivy Natal aims to provide couples, including those in same-sex relationships, with the opportunity to have genetically related children.

Membio's single-use 0.2-10 L benchtop bioreactor system uses a proprietary design to provide a constant environment for cells at all scales. One technique will provide the same outcomes at all scales, whether at 0.2 L, 10 L, or anywhere in between. Fully automated single-use bioreactors designed by the business to enable cost-effective and scalable manufacture.

Circularis Biotechnologies, Inc. is a biotechnology company founded in 2014 and headquartered in Oakland, California. The company specializes in developing innovative methods to regulate gene expression, which enhances the production yields of biotherapeutics. Circularis offers a range of products, including RACRE Variant Libraries, hCMV Variant Library, Protein expression with CMV promoters, and T7 Variant Library. In addition, it provides various services such as RACRE Enhancement, RACRE Discovery, RACRE Technology Access Program, and Ribozyme Analysis of Cis-Regulatory Elements. Through its advanced technologies and services, Circularis aims to improve the efficiency and effectiveness of biotherapeutic production.

CASPR Biotech is a San Francisco-based company established in 2018 that specializes in the development of a CRISPR-based platform for diagnosing antimicrobial resistances (AMR) and infectious diseases. The company focuses on creating portable diagnostic kits that utilize proprietary CRISPR Cas enzymes to detect specific DNA and RNA sequences, as well as signature amino acid sequences associated with infectious diseases and genetic mutations. These kits are designed to provide clinicians with a simple, fast, and affordable solution for molecular detection, enhancing the efficiency of disease identification in clinical and hospital settings.